WNT5A and cancer: Also, a hexapeptide inhibitor of Wnt5a signaling, Box5 (Jenei et al., 2009), has been employed in some cancer studies (Tu et al., 2019; Luo et al., 2020), opening a new opportunity to explore the role of non-canonical Wnt signaling in GC.